Evidence map›Paper›PMID 32657706›Full record

ArticleSouth African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde2020

Benefit v. risk when using chloroquine in patients with severe COVID-19 disease.

E H Decloedt, H Reuter, B Allwood, A Parker, C F N Koegelenberg, M Blockman, J Taljaard

Open access · goldAbstract readLetterComment
PubMed Publisher
In one paragraph

Article in South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Is there any potential management against COVID-19? A systematic review and meta-analysis.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020
    Pooled it
  2. Review
  3. Article
  4. Current evidence for directed and supportive investigational therapies against COVID-19.African journal of thoracic and critical care medicine · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

E H DecloedtDivision of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa. ericdecloedt@sun.ac.za.
H Reuter
B Allwood
A Parker
C F N Koegelenberg
M Blockman
J Taljaard
Stellenbosch University · ZAGroote Schuur Hospital · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ChloroquineCoronavirus InfectionsHydroxychloroquinePandemicsPneumonia, ViralAzithromycinBetacoronavirusCOVID-19COVID-19 Drug TreatmentHumansSARS-CoV-2AzithromycinChloroquineHydroxychloroquine

Identifiers

PMID32657706
OpenAlexW3014679621

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.